To ask the Secretary of State for Health, what the current waiting time is for non-urgent referrals for suspected breast cancer. - Inc figures.

To ask the Secretary of State for Health, what the current waiting time is for non-urgent referrals for suspected breast cancer. - Inc figures.

To ask the Secretary of State for Health, what the annual cost was in 2001-02 to the NHS to social services of supporting people who suffer vision loss as a result of wet age-related macular degeneration; what assessment he has made of the impact of patients of the delay in...

To ask the Secretary of State for Health, what the annual cost was in 2001-02 to the NHS to social services of supporting people who suffer vision loss as a result of wet age-related macular degeneration; what assessment he has made of the impact of patients of the delay in...

Westminster Hall adjournment debate on cancer networks.

Westminster Hall adjournment debate on cancer networks.

To ask the Secretary of State for Health, what assessment he has made of whether percutaneous coronary interventions with bare stents increased after the National Institute for Clinical Excellence completed its appraisal of stents in May 2000; what recent assessment he has made of the cost of readmitting patients who...

To ask the Secretary of State for Health, what assessment he has made of whether percutaneous coronary interventions with bare stents increased after the National Institute for Clinical Excellence completed its appraisal of stents in May 2000; what recent assessment he has made of the cost of readmitting patients who...

To ask the Secretary of State for Health, whether guidance has been provided to primary care trusts on the provision of drug eluting stents for use in percutaneous coronary intervention.

To ask the Secretary of State for Health, whether guidance has been provided to primary care trusts on the provision of drug eluting stents for use in percutaneous coronary intervention.

To ask the Secretary of State for Health, what the most common form of treatment is for myeloma patients.

To ask the Secretary of State for Health, what the most common form of treatment is for myeloma patients.

To ask the Secretary of State for Health, when he expects to set up a new programme for the development of cardiac units in the UK. - (Holding answer 21 June 2002).

To ask the Secretary of State for Health, when he expects to set up a new programme for the development of cardiac units in the UK. - (Holding answer 21 June 2002).

To ask the Secretary of State for Health, what recent grants the Government has made available to treating and finding a cure for myeloma; what recent research and studies the Government has undertaken to find the cause of multiple myeloma.

To ask the Secretary of State for Health, what recent grants the Government has made available to treating and finding a cure for myeloma; what recent research and studies the Government has undertaken to find the cause of multiple myeloma.

To ask the Secretary of State for Health, whether primary care trusts are obliged to wait for NICE guidance on drug eluting stents before allowing their use in patients.

To ask the Secretary of State for Health, whether primary care trusts are obliged to wait for NICE guidance on drug eluting stents before allowing their use in patients.

To ask the Secretary of State for Health, what restenosis rate is associated with the use of bare stents in the UK. - The Department does not collect data relating to the restenosis rate associated with the use of bare stents in England.

To ask the Secretary of State for Health, what restenosis rate is associated with the use of bare stents in the UK. - The Department does not collect data relating to the restenosis rate associated with the use of bare stents in England.

To ask the Secretary of State for Health, whether his Department has made an assessment of how the use of drug eluting stents will contribute to revascularisation targets set out in the National Service Framework on Coronary Heart Disease.

To ask the Secretary of State for Health, whether his Department has made an assessment of how the use of drug eluting stents will contribute to revascularisation targets set out in the National Service Framework on Coronary Heart Disease.

To ask the Secretary of State for Health, what percentage of people in England diagnosed with non-small cell lung cancer were entered into clinical trials in each of the last five years for which figures are available.

To ask the Secretary of State for Health, what percentage of people in England diagnosed with non-small cell lung cancer were entered into clinical trials in each of the last five years for which figures are available.

To ask the Secretary of State for Health, if he plans to meet patient representatives of senior ophthalmologists to discuss the implications of preliminary NICE guidance on the use of photodynamic therapy to treat age-related macular degeneration; what guidance to intends to issue to health authorities regarding patients currently being...

To ask the Secretary of State for Health, if he plans to meet patient representatives of senior ophthalmologists to discuss the implications of preliminary NICE guidance on the use of photodynamic therapy to treat age-related macular degeneration; what guidance to intends to issue to health authorities regarding patients currently being...

To ask the Secretary of State for Health, what estimate he has made of the number of patients with age-related macular degeneration eligible for treatment who have (a) lost eye sight and (b) been registered blind since visudyne received regulatory approval; how many patients are eligible for photodynamic treatment for...

To ask the Secretary of State for Health, what estimate he has made of the number of patients with age-related macular degeneration eligible for treatment who have (a) lost eye sight and (b) been registered blind since visudyne received regulatory approval; how many patients are eligible for photodynamic treatment for...

To ask the Secretary of State for Health, what plans he has to reduce the number of age-related macular degeneration patients eligible for treatment (a) losing sight and (b) registering blind owing to a lack of regional availability of visudyne; what discussions his Department has held with representatives of (a)...

To ask the Secretary of State for Health, what plans he has to reduce the number of age-related macular degeneration patients eligible for treatment (a) losing sight and (b) registering blind owing to a lack of regional availability of visudyne; what discussions his Department has held with representatives of (a)...

To ask the Secretary of State for Health, how many patients were treated with photodynamic treatment for (a) wet and (b) dry age-related macular degeneration in the (i) NHS and (ii) private sector in the last year for which figures are available. - Includes figures. (Holding answer 28 January 2002).

To ask the Secretary of State for Health, how many patients were treated with photodynamic treatment for (a) wet and (b) dry age-related macular degeneration in the (i) NHS and (ii) private sector in the last year for which figures are available. - Includes figures. (Holding answer 28 January 2002).

To ask the Secretary of State for Health, if he will make a statement on NICE's report on glutiramer acetate for multiple sclerosis.

To ask the Secretary of State for Health, if he will make a statement on NICE's report on glutiramer acetate for multiple sclerosis.